Orazipone (also known as OR-1384 or OR-1958) was developed by Orion Company as thiol-modulating, anti-inflammatory agent. Orazipone inhibits activation of inflammatory transcription factors nuclear factor-kappa B and signal transducer and activator of transcription 1 and decreases inducible nitric-oxide synthase expression and nitric oxide production in response to inflammatory stimuli. This drug had completed phase I clinical studies in Finland for possible use in inflammatory bowel disease, asthma, and chronic obstructive pulmonary disease. In addition, orazipone was studied for the treatment of Crohn's disease. However, all these studies were discontinued.